ReviewFrontiers in endocrinology2025
ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting.
Shuwei Weng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
ReviewFrontiers in endocrinology2025
Shuwei Weng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.